$AVGO

Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More

Analysts upgraded Broadcom (AVGO) to Outperform with a $490 target, Deere (DE) to Outperform with an $813 target, and Dell (DELL) to Outperform with a $625 target. Moderna (MRNA) was downgraded to Sell with an $81 target. Seaport Research initiated Buy ratings on Devon Energy (DVN), Permian Resources (PR), and Viper Energy (VNOM).

Original reporting
Published Sep 3, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 1:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More — source image
Decision brief

The 30-second read

$AVGOBullishLow
01

Why it matters

The upgrades and downgrades provide modest directional cues but lack fresh catalyst, limiting immediate trading impact.

02

Market read

A collection of rating changes across multiple sectors offers limited actionable insight; overall market impact is muted.

03

What to watch

No new fundamental catalysts; price targets rely on analyst optimism.

Relevance 5/10Novelty 3/10Timing: Thursday

Background

The article aggregates analyst rating changes and price targets released on Thursday, September 3, 2026.

Company-level read

Ticker impact

$AVGOBullishMedium confidence
Context

Broadcom was upgraded to Outperform with a $490 price target.

Expected impact

Modest upside over weeks.

Evidence & confidence

Upgrade suggests improved outlook but no new catalyst.

$DEBullishMedium confidence
Context

Deere & Company was raised to Outperform with an $813 target.

Expected impact

Modest upside.

Evidence & confidence

Analyst upgrade signals better expectations.

$DELLBullishMedium confidence
Context

Dell Technologies was upgraded to Outperform with a $625 target.

Expected impact

Limited upside.

Evidence & confidence

Upgrade reflects improved view but no immediate catalyst.

$MRNABearishMedium confidence
Context

Moderna was cut to Sell with an $81 target.

Expected impact

Potential decline toward target.

Evidence & confidence

Downgrade indicates weaker outlook.

$PCGNeutralMedium confidence
Context

PG&E was cut to Hold with a $17 target.

Expected impact

Flat to slightly lower.

Evidence & confidence

Hold rating suggests no strong move.

$RAREBearishMedium confidence
Context

Ultragenyx was downgraded to In Line with a $16 target.

Expected impact

Potential decline.

Evidence & confidence

Target cut reflects weaker expectations.

$DVNBullishMedium confidence
Context

Devon Energy was initiated with a Buy rating and $65 target.

Expected impact

Moderate upside.

Evidence & confidence

New buy initiation suggests favorable view.

$PRBullishMedium confidence
Context

Permian Resources was started with a Buy rating and $45 target.

Expected impact

Modest upside.

Evidence & confidence

Buy initiation indicates positive outlook.

Market effects

Broad upgrades in tech and energy may lift sector sentiment.

US market sentiment modestly positive on Thursday.

Limited; primarily US equity focus.

Counterpoint

Upgrades may be premature without fresh earnings data.

Key entities

  • Broadcom

    Technology semiconductor firm upgraded to Outperform.

  • Deere & Company

    Agricultural equipment maker upgraded to Outperform.

Related articles

$SMCIMed

Super Micro Falls 4% Despite Blowout Quarter as Margin Worries and Data Center Backlash Weigh; Dell Sinks 8%, Hewlett Packard Enterprise Drops 6%

Super Micro Computer (SMCI) shares fell 4% despite beating Q1 FY2027 estimates, with revenue at $19.95B and EPS at $1.81. Guidance was raised, but concerns over margins and data center regulations weighed on the stock. Dell (DELL) and Hewlett Packard Enterprise (HPE) also declined, down 8% and 6% respectively, amid broader AI hardware sector pressure.

$MRNAHigh

Moderna Soars 8% on Early Multiple Myeloma Data for Its Three-in-One mRNA Therapy

Moderna (MRNA) shares rose 8% after early data showed its experimental multiple myeloma therapy, mRNA-2808, had four confirmed responses among 11 heavily pretreated patients. The therapy aims to produce three cancer drugs simultaneously, though it is years away from competing with established treatments from Johnson & Johnson (JNJ), Pfizer (PFE), and Regeneron (REGN). The company reports third-quarter results on Friday.

$MRNAMedAI 8/10

Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study

Moderna's mRNA-1469 vaccine candidate for Bundibugyo ebolavirus (BDBV) has been recommended by the WHO to advance to a Phase 2/3 study in the DRC, following encouraging Phase 1 results. The study, supported by CEPI, aims to evaluate the vaccine's efficacy in protecting against BDBV. Moderna's CEO highlighted the potential of mRNA technology in rapidly developing vaccines for emerging infectious diseases.